Sandoz defends antitrust claims against United Therapeutics over Remodulin
MLex Summary: Sandoz filed an opposition to United Therapeutics Corporation’s motion to dismiss claims that it illegally impeded competition for the drug Remodulin, arguing that UTC breached a 2015 settlement agreement...To view the full article, register now.
Already a subscriber? Click here to view full article